Diavix
( Lamivudine Zidovudine Tablet )
Diavix® is a fixed dose combination drug containing Lamivudine and Zidovudine. Lamivudine and zidovudine are nucleoside analogues which have activity against HIV. Additionally, lamivudine has activity against hepatitis B virus (HBV). Both medicinal products are metabolised intracellularly to their active moieties, lamivudine 5'- triphosphate(TP) and zidovudine 5'- triphosphate respectively Their main modes of action are as chain terminators of viral reverse transcription. Lamivudine-TP and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2 replication in vitro. The recommended oral dose of Diavix® for adults and adolescents is one tablet twice daily.
- Shows excellent efficacy against HIV replication
- Recommended NRTI by DHHS
- Ensures patients' long-term adherence to therapy
- Lacks potential side effects of stavudine
- Preferred NRTI for patients with renal problem and ulcer
